Daiichi Sankyo Co., Ltd.

Daiichi Sankyo Co., Ltd. is a global pharmaceutical company headquartered in Tokyo, Japan, with a significant presence in the UK. Established in 2005 through the merger of Daiichi Pharmaceutical and Sankyo Company, Limited, the company has grown to become a leader in the development of innovative medicines.

The company focuses on several therapeutic areas, including oncology, cardiovascular diseases, and infectious diseases. With a commitment to research and development, Daiichi Sankyo invests heavily in discovering new treatments that address unmet medical needs.

One of the core visions of Daiichi Sankyo is to contribute to the health and well-being of people worldwide. The company aims to achieve this by leveraging cutting-edge science and technology to create effective and safe pharmaceuticals.

• Research and Development: Daiichi Sankyo prioritises R&D, with numerous ongoing clinical trials aimed at bringing new therapies to market.
• Global Reach: The company operates in over 20 countries, ensuring that its products are accessible to patients around the globe.
• Sustainability: Daiichi Sankyo is committed to sustainable practices, focusing on reducing its environmental impact while enhancing healthcare.

With a workforce of approximately 15,000 employees worldwide, Daiichi Sankyo fosters a culture of collaboration and innovation. The company believes in empowering its employees to drive progress and improve patient outcomes.

In summary, Daiichi Sankyo Co., Ltd. stands as a beacon of hope in the pharmaceutical industry, dedicated to advancing healthcare through innovative solutions and a patient-centric approach.